Rovi reported 13.2% revenue growth in H1 2026
Total revenue reached €357M, with CDMO sales up 38% and gross margin expanding 6.5 percentage points.
See the latest news and media coverage for Rovi. We track all announcements, press releases, and industry mentions in real time, all in one place.
Specialty pharmaceutical company
rovi.esLast updated
In short: Rovi reported strong H1 2026 growth, acquired a major manufacturing plant in Phoenix, and secured a strategic manufacturing deal with Roche.
Total revenue reached €357M, with CDMO sales up 38% and gross margin expanding 6.5 percentage points.
The deal strengthens Rovi's industrial base in the US and consolidates its position in aseptic filling of sterile injectables.
Operating income reaches 152.5 million euros. CDMO grows 5%, Risperidona ISM® 37%. R&D investment rises 79% to 11.2 million.
Gross margin expands 3.8 points to 62.3%. Heparin sales drop 12%, Okedi rises 37%. Updates 2026 guidance to low-to-mid single-digit growth. Announces plant acquisition completion.
The bullish streak achieved by Rovi in the wake of its earnings release does not prevent JPMorgan from continuing to accelerate its increase in short positions...
Laboratorios Farmaceuticos Rovi SA (WBO:ROVI) reports strong revenue growth and strategic acquisitions, while navigating pricing pressures and increased expenses.
MADRID, 23 (EUROPA PRESS) Laboratorios Farmacéuticos Rovi, S.A. recorded an increase in its operating income of 9.4% during the first half of 2026 in...
The pharmaceutical company records a non-recurring income of 62.4 million from the new US plant acquired from Bristol Myers Squibb. The firm raises the profit...
Track Rovi and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Rovi and other trending companies.